Home › NDC Lookup › RxCUI directory › RxCUI 105450

Metyrapone 250 MG Oral Capsule [Metopirone] — RxCUI 105450

RxNorm drug concept · Semantic branded drug
RxCUI 105450 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI105450
Official nameMetyrapone 250 MG Oral Capsule [Metopirone]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asMetopirone 250 MG Oral Capsule
FDA products mapped2
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Metyrapone 250 MG Oral Capsule [Metopirone] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Metyrapone 250 MG Oral Capsule [Metopirone] RxCUI 105450

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Metyrapone 6923
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Metopirone 203002
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Metyrapone Oral Capsule 372907
    • Metyrapone Oral Product 1164088
    • Metyrapone Pill 1164089
    • Metyrapone Oral Capsule [Metopirone] 366595
    • Metopirone Oral Product 1176949
    • Metopirone Pill 1176950
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Metyrapone 250 MG Oral Capsule SCD · 199772
  • Metyrapone 250 MG SCDC · 317429
  • Metyrapone Oral Capsule SCDF · 372907
  • Metyrapone Oral Product SCDG · 1164088
  • Metyrapone Pill SCDG · 1164089

Brand-Name Concepts

  • Metyrapone 250 MG [Metopirone] SBDC · 564064
  • Metyrapone Oral Capsule [Metopirone] SBDF · 366595
  • Metopirone Oral Product SBDG · 1176949
  • Metopirone Pill SBDG · 1176950
  • Metopirone BN · 203002

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 105450 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
68118-0455-18 18 CAPSULE, GELATIN COATED in 1 BOTTLE (68118-455-18) Metopirone ESTEVE PHARMACEUTICALS, S.A. 1962-01-25
76336-0455-18 18 CAPSULE, GELATIN COATED in 1 BOTTLE (76336-455-18) Metopirone HRA Pharma Rare Diseases 1962-01-25
Observed labelers: ESTEVE PHARMACEUTICALS, S.A. (1) · HRA Pharma Rare Diseases (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.